WO2025062359 - ONCOLYTIC ADENOVIRUS AND TOPOISOMERASE I INHIBITORS FOR USE IN TREATING A CANCER
National phase entry:
Publication Number
WO/2025/062359
Publication Date
27.03.2025
International Application No.
PCT/IB2024/059165
International Filing Date
20.09.2024
Title **
[English]
ONCOLYTIC ADENOVIRUS AND TOPOISOMERASE I INHIBITORS FOR USE IN TREATING A CANCER
[French]
ADÉNOVIRUS ONCOLYTIQUES ET INHIBITEURS DE TOPOISOMÉRASE I DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT D'UN CANCER
Applicants **
THERIVA BIOLOGICS, S.L.
Inventors
CONNELLY, Sheila
MATO BERCIANO, Ana
Priority Data
63/584,003
20.09.2023
US
63/624,896
25.01.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2982 | |
| EPO | Filing, Examination, Granting | 19169 | |
| Japan | Filing, Examination, Granting | 2740 | |
| South Korea | Filing, Examination, Granting | 3290 | |
| USA | Filing, Examination, Granting | 7540 |
Total:
35,721
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure relates, inter alia, to combination therapies of an oncolytic adenovirus with a topoisomerase I inhibitor or prodrug thereof, such as topotecan or SN-38, or a prodrug of a topoisomerase inhibitor, such as irinotecan, for treating or preventing ovarian, cervical, lung, colon or colorectal, and/or pancreatic cancer.[French]
La présente divulgation concerne, entre autres, des polythérapies d'un adénovirus oncolytique avec un inhibiteur de topoisomérase I ou un promédicament correspondant, tel que le topotécan ou le SN-38, ou un promédicament d'un inhibiteur de topoisomérase, tel que l'irinotécan, pour le traitement ou la prévention du cancer de l'ovaire, du col de l'utérus, du poumon, du côlon ou du côlon et du rectum, et/ou du pancréas.